An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
dividends
Rhea-AI Summary
Gilead Sciences, Inc. (NASDAQ: GILD) has declared a 2.7% increase in its quarterly cash dividend, now set at $0.75 per share. This increase will begin in the first quarter of 2023, with dividends payable on March 30, 2023 to stockholders on record by March 15, 2023. Future dividends are contingent on Board approval. Gilead continues to focus on innovative medicines for serious diseases, including HIV and cancer, operating in over 35 countries globally.
Positive
Quarterly cash dividend increased by 2.7% to $0.75 per share.
Demonstrates confidence in financial health and commitment to shareholders.
Negative
Future dividends are subject to Board approval, introducing uncertainty.
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2023. The increase will result in a quarterly dividend of $0.75 per share of common stock. The dividend is payable on March 30, 2023, to stockholders of record at the close of business on March 15, 2023. Future dividends will be subject to Board approval.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.